Investors

Press Releases

ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program

January 11, 2021

– European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 – Phase 3 EDELWEISS…

Read more

ObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 – 14, 2021

January 7, 2021

Geneva, Switzerland and Boston, MA – January 7, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…

Read more

ObsEva appoints David Renas as Chief Financial Officer

January 4, 2021

Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more
 
 

Sign up for news

 
 

    * Type:


    InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












    Read our privacy policy here.


     

    Are you sure you want to leave ObsEva.com?

    We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

    Continue to link

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue